The present paper reviewed the literature data about the prognostic relevance of mutational status and/or immunohistochemical expression of p53, PTEN, PIK3, mTOR, ¦Â-catenin, k-ras and RASSF1A, microsatellite instability, vascular endothelial growth factor expression, DNA aneuploidy, and serum assay of CA125 and other tumor associated antigens. Tissue and serum biomarkers could be used, in addition to the conventional clinical-pathological variables, for the stratification of patients into categories with different risk of recurrence to better tailor adjuvant treatment.